SPAC Market Continues Recovery & Biggest SPAC Discounts for Thursday
The SPAC market has come back to an equilibrium where pre-deal SPACs trade close to NAV, good deals get rewarded, post-announcement execution can drive big returns, and strong IPOs could see high demand and a little pop too.
Author:
Apr 8, 2021
SPAC investors should be pleased with how the SPAC market went from peak SPAC just a few months ago to operating efficiently. There is still more to get cleared out and any combination of bad deals, silly IPOs, or bad news could change the mood, but for now investors will have confidence in the way it is operating.
Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed by NeuroRx as ZYESAMI™ in collaboration with Relief Therapeutics Holding, AG . The trial, designated as …
– NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed by NeuroRx as ZYESAMI™ in collaboration with Relief Therapeutics Holding, AG (SIX: RLF, OTCQB: RLFTF). The trial, designated as TESICO ( T h e rapeutics for S everely Ill I npatients with CO VID-19), is funded by the US Government COVID-19 Therapeutics R
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
SPAC Opportunities for Thursday
The flow of new SPACs and rapid fire deals has finally slowed. This will give SPAC investors an opportunity to invest strategically as we go forward in 2021.
Author:
Union Acquisition Corp II (LATN) agreeing to a $1.1B EV deal with
Procaps, a LatAm Pharmaceuticals company gives continued relief to overwhelmed SPAC investors. Everyone in the SPAC market had simply become exhausted by the pace of new filings, new IPOs, and often irrational prices.
With the market slowing, investors will have an opportunity to take a breath and do their homework to (a) identify high conviction SPACs and (b) carefully monitor them across the lifecycle to take advantage of the inherent yield plus optionality play that SPACs offer.